title: Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea.
abstract: BACKGROUND
  Racial disparities in incidence rate as well as risk factors for venous thromboembolism (VTE) exist between Asian and Western populations. Moreover, predictors for recurrent VTE were not identified in Asians. Thus, this study was undertaken to investigate risk factors for recurrent VTE events in Korean people.
  
  
  METHODS
  Three hundred-three patients newly diagnosed as VTE were enrolled from Seoul National University Hospital. Recurrence rate based on risk factors for VTE were investigated. Cumulative incidence of recurrent VTE was calculated by the Kaplan and Meier method. Independent predictors for VTE were determined using Cox proportional hazards model.
  
  
  RESULTS
  After a median follow-up of 44 months, 24 (8%) of 303 patients relapsed for a total observation time of 1,217 patient-year. Cumulative incidences of recurrent VTE were 3% at 1 year, 10% at 5 years, and 18% at 8 years. Independent predictors for recurrent VTE were presence of residual thrombosis (hazard ratio [HR]=3.1, 95% confidence interval [CI] 1.0-9.3; p=0.044), antiphospholipid syndrome (APS) (HR=4.3, 95% CI 1.0-19.0; p=0.052), and age 50 years or younger (HR=2.5, 95% CI 1.0-6.6; p=0.053) by multivariate analysis. Residual thrombosis and APS remained predictive of recurrence by the anticoagulation-period stratified analysis.
  
  
  CONCLUSIONS
  In contrast to Western populations, Korean patients with VTE had the lower recurrent rate. Extended anticoagulation is necessary for Korean patients with residual thrombosis or APS.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Tae Min
authors.initials: TM
authors.lastname: Kim
authors.forename: Jin Soo
authors.initials: JS
authors.lastname: Kim
authors.forename: Sae Won
authors.initials: SW
authors.lastname: Han
authors.forename: Yong Sang
authors.initials: YS
authors.lastname: Hong
authors.forename: Inho
authors.initials: I
authors.lastname: Kim
authors.forename: Jongwon
authors.initials: J
authors.lastname: Ha
authors.forename: Sang Joon
authors.initials: SJ
authors.lastname: Kim
authors.forename: Jin Wook
authors.initials: JW
authors.lastname: Chung
authors.forename: Jae Hyung
authors.initials: JH
authors.lastname: Park
authors.forename: Dongsoon
authors.initials: D
authors.lastname: Lee
authors.forename: Seonyang
authors.initials: S
authors.lastname: Park
authors.forename: Byoung Kook
authors.initials: BK
authors.lastname: Kim
authors.forename: Noe Kyeong
authors.initials: NK
authors.lastname: Kim
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Yoon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D044466:Asian People; D002648:Child; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007723:Korea / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D015912:Thrombolytic Therapy; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D055815:Young Adult
chemical_list: D000925:Anticoagulants